Neurocrine Biosciences (NBIX) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Neurocrine Bio. (NBIX) PT Raised to $100 at Oppenheimer
February 14, 2018 6:21 AM ESTOppenheimer raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $95.00) while maintaining a Outperform rating following Q4 results.
Analyst Jay Olson commented, "NBIX shares have outperformed YTD (+8% vs. NBI +1% and S&P 500 flat), largely driven by impressive 4Q17 sales of... More
